Literature DB >> 10454674

Change in antibiotic resistance of group B streptococcus: impact on intrapartum management.

W J Morales1, S S Dickey, P Bornick, D V Lim.   

Abstract

OBJECTIVE: Intrapartum chemoprophylaxis has resulted in a significant reduction of group B Streptococcus neonatal infection. For penicillin-allergic patients, clindamycin or erythromycin is the recommended antibiotic. The purpose of this study was to establish any pattern of antibiotic resistance of group B streptococcal clinical isolates over the past 15 years. STUDY
DESIGN: Group B streptococcal isolates obtained from the lower genital tract were tested for sensitivity to ampicillin, penicillin, clindamycin, and erythromycin. The sensitivity of 100 group B streptococcal isolates retrieved in the period 1997-1998 was compared with that of 85 group B streptococcal isolates from 1980-1993.
RESULTS: From 1980-1993 group B streptococcal isolates were available for testing for antibiotic resistance along with 100 isolates from a second study period 1997-1998. Of the 100 group B streptococcal isolates from 1997-1998, 18 were resistant to erythromycin, of which 5 were also resistant to clindamycin, as compared with 1 of the 85 isolates from 1980-1993 that was resistant to erythromycin (P <.001). All the isolates were sensitive to ampicillin and penicillin. All 18 resistant strains from 1997-1998 were found to be sensitive to cephalothin.
CONCLUSION: Over the past 18 years there has been increased in vitro resistance of group B streptococci to both clindamycin and erythromycin. If other studies confirm these findings, modifications to the current Centers for Disease Control and Prevention recommendations may be necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454674     DOI: 10.1016/s0002-9378(99)70553-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  29 in total

1.  Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study.

Authors:  D De Mouy; J D Cavallo; R Leclercq; R Fabre
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan.

Authors:  P R Hsueh; L J Teng; L N Lee; S W Ho; P C Yang; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

3.  Molecular epidemiology of macrolide resistance in neonatal bloodstream isolates of group B streptococci.

Authors:  Daniel J Diekema; Janet I Andrews; Holly Huynh; Paul R Rhomberg; Stella R Doktor; Jill Beyer; Virginia D Shortridge; Robert K Flamm; Ronald N Jones; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

4.  Mechanisms of macrolide resistance in clinical group B streptococci isolated in France.

Authors:  F Fitoussi; C Loukil; I Gros; O Clermont; P Mariani; S Bonacorsi; I Le Thomas; D Deforche; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  High rates of perinatal group B Streptococcus clindamycin and erythromycin resistance in an upstate New York hospital.

Authors:  Ephraim E Back; Elisa J O'Grady; Joshua D Back
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

6.  A serotype V clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a southwestern region of Germany.

Authors:  Ulrich von Both; Michael Ruess; Urban Mueller; Kirsten Fluegge; Anna Sander; Reinhard Berner
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

7.  Antimicrobial susceptibilities of group B streptococci in New Zealand.

Authors:  Anja M Werno; Trevor P Anderson; David R Murdoch
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Heterogeneity of genotype-phenotype correlation among macrolide-resistant Streptococcus agalactiae isolates.

Authors:  Ulrich von Both; Anna Buerckstuemmer; Kirsten Fluegge; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 9.  Molecular-based screening for perinatal group B streptococcal infection: implications for prevention and therapy.

Authors:  Stéphane Emonet; Jacques Schrenzel; Begoña Martinez de Tejada
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

10.  The crystal structure analysis of group B Streptococcus sortase C1: a model for the "lid" movement upon substrate binding.

Authors:  Baldeep Khare; Zheng-Qing Fu; I-Hsiu Huang; Hung Ton-That; Sthanam V L Narayana
Journal:  J Mol Biol       Date:  2011-10-18       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.